Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Safety and Tolerability of Sildenafil in Patients with Eisenmenger Physiology

    Summary
    EudraCT number
    		 2006-004705-26
    Trial protocol
    		 GB  
    Global end of trial date
    27 Feb 2009

    Results information
    Results version number
    		 v1(current)
    This version publication date
    06 Jun 2020
    First version publication date
    06 Jun 2020
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    CRO529
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Imperial College London
    Sponsor organisation address
    South Kensington Campus, London, United Kingdom, SW7 2AZ
    Public contact
    PROFESSOR MICHAEL GATZOULIS, Imperial College London, +44 (0)20 7352 8121, m.gatzoulis@imperial.ac.uk
    Scientific contact
    PROFESSOR MICHAEL GATZOULIS, Imperial College London, +44 (0)20 7352 8121, m.gatzoulis@imperial.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Feb 2010
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    27 Feb 2009
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Feb 2009
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To examine safety and tolerability of oral sildenafil in patients with Eisenmenger physiology. Primary endpoint: Effects of sildenafil on systemic oxygen saturation in patients with pulmonary arterial hypertension related to Eisenmenger physiology
    Protection of trial subjects
    None
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Apr 2008
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 12
    Worldwide total number of subjects
    12
    EEA total number of subjects
    12
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    12
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Patients with Eisenmenger physiology (non-restrictive intra- or extra-cardiac communication with a right-to-left shunt at rest), in New York Heart Association (NYHA) class III and followed at a single tertiary center were recruited. Twelve patients with Eisenmenger physiology were recruited between April 2008 and February 2009.

    Pre-assignment
    Screening details
    		 All participants were admitted to the hospital for 2 days at the start of the study. Baseline assessment consisted of a QoL questionnaire, transthoracic echocardiogram, six-minute walk test (6MWT) and blood test.

    Period 1
    Period 1 title
    Overall (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded
    Blinding implementation details
    Open-label study

    Arms
    Arm title
    		 all patients
    Arm description
    		 All participants received Sildenafil for 3 months.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Sildenafil
    Investigational medicinal product code
    Other name
    Revatio ® 20 mg film-coated tablets
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    20 mg three times daily for 3 months

    Number of subjects in period 1
    		all patients
    Started
    12
    Completed
    12

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall
    Reporting group description
    		 -

    Reporting group values
    		 Overall Total
    Number of subjects
    		 12 12
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    		 12 12
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 34.3 ( 10.2 ) -
    Gender categorical
    Units: Subjects
        Female
    		 10 10
        Male
    		 2 2

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    all patients
    Reporting group description
    		 All participants received Sildenafil for 3 months.

    Subject analysis set title
    Baseline
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Baseline data of the participants

    Primary: Oxygen saturation

    		 Close Top of page
    End point title
    		 Oxygen saturation
    End point description
    End point type
    Primary
    End point timeframe
    3 months
    End point values
    		 all patients Baseline
    Number of subjects analysed
    12
    12
    Units: percent
        arithmetic mean (standard deviation)
    82.6 ( 11 )
    83.8 ( 3.8 )
    Statistical analysis title
    		 Oxigen saturation
    Statistical analysis description
    Baseline compare to 3 months
    Comparison groups
    all patients v Baseline
    Number of subjects included in analysis
    24
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.76
    Method
    		 Fisher exact
    Confidence interval

    Secondary: Camphor scores Symptoms

    		 Close Top of page
    End point title
    		 Camphor scores Symptoms
    End point description
    End point type
    Secondary
    End point timeframe
    3 months
    End point values
    		 all patients Baseline
    Number of subjects analysed
    12
    12
    Units: scores
        arithmetic mean (standard deviation)
    5.3 ( 3.6 )
    11 ( 2.7 )
    Statistical analysis title
    		 Symptome scores
    Statistical analysis description
    Compare baseline to 3 months
    Comparison groups
    all patients v Baseline
    Number of subjects included in analysis
    24
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.002
    Method
    		 Fisher exact
    Confidence interval

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    3 months
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    10
    Reporting groups
    Reporting group title
    all patients
    Reporting group description
    		 All participants received Sildenafil for 3 months.

    Serious adverse events
    		 all patients
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 12 (16.67%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Cardiac disorders
    Transient asymptomic hypotension
         subjects affected / exposed
    1 / 12 (8.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrial tachycardia
         subjects affected / exposed
    1 / 12 (8.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 all patients
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 12 (91.67%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    5 / 12 (41.67%)
         occurrences all number
    5
    Respiratory, thoracic and mediastinal disorders
    Nasal congestion
         subjects affected / exposed
    2 / 12 (16.67%)
         occurrences all number
    2
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    4 / 12 (33.33%)
         occurrences all number
    4

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references
    http://www.ncbi.nlm.nih.gov/pubmed/20304507
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 01:50:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA